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ABSTRACT 
Colorectal cancer (CRC) is one of the deadliest types of cancer in the US due to 
its high incidence and mortality rates. Detection of CRC in the early stages through 
available screening tests increases the patient's survival chances. In this study, we 
investigate the cost-effectiveness of a wide variety of multi-modal CRC screening 
policies. More specifically, we develop a Monte Carlo simulation framework to model 
the CRC natural history and preventive interventions. Age-specific and size-specific 
progression rates of adenomatous polyps are estimated using an innovative active 
learning method.  Specifically, we develop a decision tree model to estimate size-specific 
and age-specific adenoma progression and regression rates. Compared to traditional 
methods, the proposed calibration process expedites the searching of the model parameter 
space significantly. CRC age-specific incidence rates and CRC stage distribution are the 
two output measures used in the calibration process. Seventy-eight CRC screening 
policies are applied to a cohort of U.S. male population using the simulation model and 
compared in terms of expected Quality Adjusted Life Years (QALY) and costs. Eleven 
policies are identified as efficient frontier policies. Among these 9 are identified as cost-
effective at the willingness to pay (WTP) threshold of $50,000. Fecal Occult Blood Test 
(FOBT) biennially in conjunction with one time Colonoscopy at 60, FOBT biennially 
along with one time Colonoscopy at 50, Fecal Immunochemical Test (FIT) biennially in 
conjunction with two times Flexible Sigmoidoscopy (FS) at 60 and 65. FIT biennially 
iv 
with one time Colonoscopy at 65, Colonoscopy at 50, 60 and 70, FOBT biennially along 
with two times Colonoscopy at 55 and 65, FOBT annually with 2 times FS at 70 and 75, 
FOBT annually in conjunction with FS at 50 and 55, and FIT biennially along with FS 
every 5 years are the nine identified cost-effective policies. 
 GS Form 14 
  (5/03) 
APPROVAL FOR SCHOLARLY DISSEMINATION 
The author grants to the Prescott Memorial Library of Louisiana Tech University 
the right to reproduce, by appropriate methods, upon request, any or all portions of this 
Thesis. It is understood that “proper request” consists of the agreement, on the part of the 
requesting party, that said reproduction is for his personal use and that subsequent 
reproduction will not occur without written approval of the author of this Thesis. Further, 
any portions of the Thesis used in books, papers, and other works must be appropriately 
referenced to this Thesis.  
Finally, the author of this Thesis reserves the right to publish freely, in the 
literature, at any time, any or all portions of this Thesis. 
 
Author: Amirhosein Fouladi 
Date: February 14, 2019 
 
 
 
vi 
 
TABLE OF CONTENTS 
ABSTRACT ....................................................................................................................... iii 
APPROVAL FOR SCHOLARLY DISSEMINATION ..................................................... v 
LIST OF FIGURES ......................................................................................................... viii 
LIST OF TABLES ............................................................................................................. ix 
CHAPTER 1 INTRODUCTION ........................................................................................ 1 
1.1 Active Learning as a Simulation Calibration Tool ............................................. 6 
CHAPTER 2 LITERATURE REVIEW ........................................................................... 10 
CHAPTER 3 METHODOLOGY ..................................................................................... 17 
1.3 CRC Natural History Model ............................................................................. 17 
3.2 CRC Natural History Simulation Model .......................................................... 19 
3.3 Screening Module Simulation .......................................................................... 20 
3.4 Model Calibration Process ................................................................................ 22 
3.4.1 Characterization of the Training Data ........................................................... 24 
3.4.2 Decision Tree Model..................................................................................... 27 
CHAPTER 4 MODEL PARAMETER ESTIMATION ................................................... 30 
4.1 Calibration Results ............................................................................................ 30 
4.2 Other Parameters ............................................................................................... 34 
CHAPTER 5 NUMERICAL RESULTS .......................................................................... 36 
CHAPTER 6 CONCLUSION........................................................................................... 44 
APPENDIX A MODEL PARAMETERS USED IN THE SIMULATION MODEL . 46 
APPENDIX B PROGRAMMING CODE OF THE MODEL ..................................... 50 
vii 
BIBLIOGRAPHY ............................................................................................................. 64 
 
viii 
 
LIST OF FIGURES 
Figure ‎1-1: Learning cycle of a schematic supervised active learning model (City 
University of Hong Kong 2018). ........................................................................................ 8 
Figure 3-1: Proposed Markov model representing dynamics of adenomatous polyps. ... 18 
Figure 3-2: CRC natural history simulation framework .................................................. 20 
Figure 3-3: Endoscopic-based CRC screening module of the simulation model. ........... 22 
Figure 3-4: Stool-based CRC screening module of the simulation model. ..................... 22 
Figure ‎3-5: An overview of the calibration process. ....................................................... 23 
Figure ‎3-6: A schematic decision tree. ............................................................................ 28 
Figure ‎4-1: Age specific estimated incidence rates using DT (red) and incidence rates 
reported by SEER (blue). .................................................................................................. 33 
Figure ‎4-2: CRC stage distribution obtained by the calibration model compared with 
those reported by SEER. ................................................................................................... 33 
Figure 5-1: Efficient frontier versus the in-practice policies. .......................................... 38 
  
 
ix 
 
LIST OF TABLES 
Table ‎1-1: In-practice screening policies recommended by different health agencies. ..... 5 
Table ‎2-1: Specifications of the similar studies published in the literature. .................... 16 
Table 3-1: Schematic envelopes formed around an incidence rate and their associated 
scores................................................................................................................................. 25 
Table ‎4-1: List of the tolerances and scores obtained in the model tunning process. ...... 32 
Table ‎4-2: Data source and estimated parameters used in the simulation model. ........... 35 
Table 5-1: Cost, QALYs, and ICER associated with the investigated policies. .............. 40 
Table 5-2: In-practice policies and best identified alternative policies in terms of the 
expected QALYs, incidence reduction, and mortality reduction - number in 
parentheses represent confidence intervals (CI). .............................................................. 43 
Table A-1: Age-specific pre-cancer transition probabilities ............................................ 46 
Table A-2: Age-specific cancer states transiotion probabilities. ..................................... 47 
Table A-3: Stage-specific life expectancy of CRC patients. ........................................... 48 
Table A-4: Age-specific mean sojourn time. ................................................................... 49 
Table A-5: Screening sensitivities. .................................................................................. 49 
Table A-6: CRC stage-specific treatment costs. .............................................................. 49 
 
 1 
 
CHAPTER 1 
 
INTRODUCTION 
 
Colon and rectal cancer are often grouped together and called colorectal cancer 
(CRC) since they have many features in common (American Cancer Society 2018). It is 
estimated that in 2018, more than 140,000 people are diagnosed with CRC and more than 
50,000 patients are dead from CRC (National Cancer Institute 2018a). More than 8% of 
cancer incidences and deaths are estimated to be CRC related (National Cancer Institute 
2018a). According to the Surveillance, Epidemiology, and End Result (SEER) program 
1975-2015 review, between 2011 and 2015, approximately 9% of all new cancer cases 
are CRC and about 9% of all cancer-related deaths are due to CRC, making it the second 
deadliest cancer and the fourth most common cancer among all different types of cancer. 
CRC starts with a polyp in the innermost layer of the colon or rectum and may grow 
through other layers of the colon if not detected and treated (American Cancer Society 
2018). There are two main types of polyp in the colon and rectum. Adenomatous polyps, 
also called adenomas, are the type which can develop to cancer. The second type of 
polyps is hyperplastic and inflammatory polyps which generally do not develop into 
cancer (American Cancer Society 2018). While in the wall of the colon or rectum, cancer 
cells may spread to adjacent lymph nodes or distant body parts through the blood or 
lymph vessels. Stages of CRC are based on how deep they have grown into the colon or 
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rectum wall or how far they have traveled outside of their organ of origin (American 
Cancer Society 2018).  
CRC mortality risk can be reduced through detection of cancer in early stages 
when there is a higher survival chance. The overall five-year surveillance rate for CRC is 
64.6%. This ratio for cases who are diagnosed in the localized and distant stage is 90% 
and 13.9%, respectively. These ratios show the importance of detecting CRC in an early 
stage. Currently, there are several early CRC detection screening tests available, such as 
Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), Flexible 
Sigmoidoscopy (FS), and colonoscopy (Lansdorp-Vogelaar et al. 2011). These tests vary 
in different features. Sigmoidoscopy and colonoscopy use a camera on a flexible tube 
introduced through the anus to examine the colon and rectum for abnormal growths. 
These tests are categorized into visual (structural) exams since they look at the structure 
inside the colon and rectum for any abnormal areas that might be cancer or adenomas. 
Sigmoidoscopy is performed on an alert patient and reaches at most the first third of the 
large colon. Any polyps detected are recorded (and maybe removed and biopsied) and the 
patient is generally referred for colonoscopy. Colonoscopy is the most aggressive and 
expensive procedure performed on a sedated patient, and permits an examination of the 
entire colon. During a colonoscopy, any suspicious polyps can be removed, which may 
prevent cancer occurrence in the future (National Cancer Institute 2018b). FIT and FOBT 
are stool-based tests and look for evidence of occult (hidden) blood in the stool. FIT 
reacts to the part of the human hemoglobin protein, found in red blood cells. FOBT 
detects occult blood in the stool through a chemical reaction, in a different way than FIT. 
Neither FIT nor FOBT can specify if the blood is from the colon or other parts of the 
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digestive tract since the blood can be from cancers or polyps or some other non-CRC-
related causes (American Cancer Society 2018). Therefore, a positive FIT or FOBT 
requires a follow-up colonoscopy. One of the weaknesses associated with FIT and FOBT 
is low specificity which results in higher false positives in test results. The associated 
high false positive results increase the number of unnecessary colonoscopy tests (Lejeune 
et al. 2014). To avoid false positive results, patients are required to follow some dietary 
restrictions before FOBT tests. However, no dietary restriction is required before FIT 
(American Cancer Society 2018). Stool-based tests are usually associated with low costs 
which come with lower sensitivity as well (Knudsen et al. 2016; Prakash et al. 2017). 
Currently, there is no evidence on which CRC screening policy is most effective 
in early detection of CRC cases at the population level (Prakash et al. 2017; Stracci et al. 
2014). A review of the current literature on CRC screening shows that clinicians need 
more guidance to choose the best screening policy for their patients based on the patient's 
different risk factors such as age, sex, and health condition. This is also manifested as a 
result of the differences in CRC screening tests and thereby different utility levels of 
these tests for patients with different risk factors. Multi-modal screening policies can 
benefit patients by providing more diverse screening options with different sensitivity 
and specificity based on the patient's risk. For example, a screening strategy which 
recommends stool-based tests at younger ages and colonoscopy at older ages can be a 
potential improvement for a low-risk patient compared to only colonoscopy screening 
policy since the stool-based tests are less aggressive (Dinh et al. 2013). Table ‎1-1 
presents the in-practice CRC screening guidelines recommended by different health 
agencies in the US. It includes the most recent in-practice screening policies provided by 
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the United States Preventive Service Task Force (USPSTF), the US Multi-Society Task 
Force (USMSTF), and the American Cancer Society (ACS). All three agencies 
recommend patients start screening at age 50. None of the three health agencies 
recommend individuals older than 75 to undergo any screening unless under special 
circumstances. Among the nine policies listed in Table ‎1-1, only one policy 
recommended by the USPSTF is a multi-modal policy recommending a mixture of 
screening tests. 
5 
Table ‎1-1: In-practice screening policies recommended by different health agencies. 
Agency Age Recommended Test Frequency 
USPSTF 
50-75 
FOBT 
Colonoscopy  
FS-FOBT 
Annually 
Every 10 years 
FS every 5 years 
along with FOBT 
every 3 years 
76-85 
The USPSTF recommends against routine 
screening for colorectal cancer in adults 76 to 
85 years of age. There may be considerations 
that support colorectal cancer screening in an 
individual patient.  
NA 
85+ 
The USPSTF recommends against screening 
for colorectal cancer in adults older than age 
85 years. 
NA 
ACS 
50-75 
FIT 
FOBT 
Multi-target stool DNA test  
Colonoscopy 
CT Colonography 
FS 
Annually 
Annually 
Every 3 years 
Every 10 years 
Every 5 years 
Every 5 years 
76-85 
The ACS recommends that clinicians 
individualize CRC screening decisions for 
individuals based on patient preferences, life 
expectancy, health status, and prior screening 
history 
NA 
85+ 
The ACS recommends that clinicians 
discourage individuals over age 85 from 
continuing CRC screening 
NA 
USMSTF 50-75 
Colonoscopy 
FIT 
CT Colonography 
FIT-fecal DNA test 
FS 
Capsule colonoscopy 
Every 10 years 
Annually 
Every 5 years 
Every 3 years 
Every 5 years 
Every 5 years 
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1.1 Active Learning as a Simulation Calibration Tool 
Simulation models must be adequately calibrated to ensure a valid representation 
of the actual system. A review of the literature shows that more than 85% of the cancer 
simulation models used a calibration method to adjust their output (Stout et al. 2009). 
Trial and error, random sampling, and grid search are some of the popular approaches 
used (Stout et al. 2009). Although these methods work for simple simulation models, they 
are not efficient enough or even practical for more complex models with a large 
parameter set. Grid search and random search, specifically, conduct an extensive search 
in the parameters solution space. This makes these methods very intriguing for smaller 
simulation models, but very time-consuming and sometimes impractical for more 
complex simulation models. The extensive search of the parameter combinations can be 
avoided by identifying smaller neighborhoods which are more likely to contain the 
"optimum" combinations. Hence, machine learning methods such as decision tree 
algorithms or regression models can be used to search the parameter set more efficiently 
(Cevik et al. 2016). Active learning (also known as query learning) is considered as a 
sub-field of machine learning and, more generally, artificial intelligence. As it is shown 
in Figure ‎1-1, the key concept of active learning is that the learning algorithm is able to 
interactively query the user (or some other information source) to obtain the desired 
outputs at new data points. This results in an improved performance with less training 
(Russell and Norvig 2016). Supervised learning is the machine learning task of learning a 
function that maps an input to an output based on sample input-output pairs (Russell and 
Norvig 2016). Each example is a pair consisting of an input object (typically a vector) 
and the desired output value. A supervised learning algorithm analyzes the training data 
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and produces a function, which can be used for mapping new examples. An optimal 
scenario will allow for the algorithm to correctly determine the class labels for unseen 
instances. This requires the learning algorithm to generalize from the training data to 
unseen situations in a reasonable way (Mohri et al. 2012). For any supervised learning 
system to perform well, it must often be trained on a large set of labeled instances. 
Sometimes these labels come at little or no cost, but for many other sophisticated 
supervised learning tasks, labeled instances are very difficult, time-consuming, or 
expensive to obtain. Therefore, the ability to learn with less data is considered a desirable 
property for learning algorithms (Settles 2012). Active learning algorithms enable the 
calibration models to efficiently choose a better combination of parameters to guide the 
model outputs to the output measure targets in clinical reports. The idea of the use of 
active learning in simulation calibration process was first introduced by Cevik et al. 
(2016). In that study authors used active learning to calibrate a breast cancer simulation 
model developed at the University of Wisconsin. A small set of evaluated parameters are 
labeled with a scoring approach to train an artificial neural network as a prediction 
model. The prediction model is used to constrain parameter combinations to a smaller 
neighborhood where parameters are more likely to produce the desired output.  
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Figure ‎1-1: Learning cycle of a schematic supervised active learning model (City University 
of Hong Kong 2018). 
In this study, we investigate the cost-effectiveness of a wide range of multi-modal 
CRC screening policies. Moreover, we conduct a comprehensive evaluation of in-practice 
policies listed in Table ‎1-1. The alternative policies are compared with the in-practice 
policies. To the best of our knowledge, current studies on CRC screening policy cost-
effectiveness analysis are limited in the extent of the details in capturing the disease 
dynamics in pre-cancerous stages. In this study, age-specific and stage-specific pre-
cancerous progression and regression rates are estimated using an innovative active 
learning approach. More specifically, the main contributions of this study are as follows. 
1) We developed a detailed CRC natural history model which captures the dynamics of 
pre-cancerous states as well as the cancer states. The proposed model incorporates three 
different adenomatous polyps’ sizes and the possibility of adenomas’ regression. The 
proposed detailed model enables us to study the disease dynamics and the impact of 
possible intervention more precisely. 2) We estimated the parameters of the detailed 
proposed natural history model using innovative active learning methods. Currently, there 
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is no detailed data available to estimate age and stage specific transition rates in the pre-
cancerous states. As a result, the existing models use simplified models in characterizing 
the CRC natural history which may introduce some bias in the corresponding analysis. In 
this study, using active learning, specifically decision trees, we devise a more efficient 
and faster calibration process to estimate the detailed natural history model parameters. 3) 
We investigated the cost-effectiveness of a variety of CRC screening policies. Screening 
policies are generated based on different screening tests’ features and the disease 
dynamics in the average-risk population. Policies are designed as a combination of stool-
based and visual screening tests to take advantage of both types of tests. 
This thesis is structured as follows. In ‎CHAPTER 2 we present a review of the 
literature on the effectiveness and cost-effectiveness analysis of CRC screening 
strategies. In ‎CHAPTER 3, the proposed CRC natural history and intervention simulation 
models are presented.  The proposed method for simulation calibration is also presented 
in this section. Parameters estimation details are discussed in ‎CHAPTER 4. Numerical 
results are presented in ‎CHAPTER 5 followed by the conclusion presented in ‎CHAPTER 
6. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
A review of the studies on the effectiveness/cost-effectiveness of CRC screening 
policies is given by Lansdorp-Vogelaar et al. (2011), Patel and Kilgore (2015), and 
Pignone et al. (2002). Table ‎2-1 lists studies that are most relevant to ours and their 
models’ specifications. Currently, most of the recommended screening guidelines, 
suggested by recent studies and in-practice screening policies, are uni-modal (Dinh et al. 
2013; Sharaf and Ladabaum 2013). A partially observed Markov chain (POMC) model is 
developed by Li et al. (2014) to evaluate the cost-effectiveness of colonoscopy and 
determine the effect of the length of the intervals between colonoscopy tests. They 
developed a natural history model which includes three pre-cancerous states (small, 
medium, and large adenomas). Cancer states are categorized into localized, regional, and 
distant cancers. All three cancerous states are divided into clinical and preclinical states. 
However, adenoma regression is not included in the proposed model. Data are taken from 
literature and the model is calibrated against clinical data of a specific group of patients. 
Their results show that colonoscopy intervals have a significant impact on the cost-
effectiveness of the screening policies. Vijan et al. (2007) has also developed a Markov 
model to evaluate the performance of three uni-modal screening policies: CT 
colonography every 5 years, CT colonography every 10 years and colonoscopy every 10 
years. Cancer states are similar to the model presented by Li et al. (2014); however, this 
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model divides the pre-cancerous states based on the risk of becoming cancer into low-risk 
polyps and high-risk polyps. Transition rates from high-risk adenoma to cancer are 
assumed to be 100%. No calibration method is used and the possibility of adenomatous 
polyps’ regression and symptomatic cancers are not considered in the proposed model. 
Screening policies are compared based on diagnostic accuracy in detecting polyps and 
cancer tissues. They found that CT colonography every 5 or 10 years is cost-effective 
compared to no-screening policy. However, colonoscopy every 10 years between the age 
of 50 and 80 is still the most cost-effective policy. Pil et al. (2016) developed a Markov 
model to analyze the cost-effectiveness of biennial FOBT for both men and women aged 
56 to 74. Incremental cost-effectiveness ratio (ICER), when compared with no-screening 
policy, is used to evaluate the policy. They adopted the tumor, node, and metastasis 
(TNM) tumor classification system for CRC modeling. TNM is a CRC stage 
classification system presented by the American Joint Committee on Cancer (AJCC). 
Adenomatous polyps in the proposed model are assumed to be low-risk or high-risk. 
Results show that for the tested policies, the probability of being cost-effective is 100% 
for men and 97% for women. This study does not incorporate the possibility of adenoma 
regression and symptomatic cancer in the CRC modeling. Van Rossum et al. (2011) 
developed a Markov model to evaluate the cost-effectiveness of one round of FOBT 
compared to one round of FIT for patients aged between 50 and 75.  Similar to Pil et al. 
(2016), they adopted the TNM classification system for cancer states modeling and 
assumed that there is only one pre-cancerous state as advanced adenoma. No calibration 
method is discussed in Pil et al. (2016) and Van Rossum et al. (2011). However, they 
performed sensitivity analysis to assess the outputs’ sensitivity to changes in the value of 
12 
the parameters with a high level of uncertainty. The result shows that among the tested 
policies, FIT outperforms FOBT while both policies are shown to be cost-effective versus 
no-screening. Lee and Park (2016) developed a Markov model to evaluate the cost-
effectiveness of annual FOBT and its effect on health disparity compared to no-screening 
policy. They used a very simplified natural history model including only three states: 
polyp, early cancer, and advanced cancer. The proposed model used in this study does 
not incorporate the effect of symptomatic cancer in the natural history, and there is no 
calibration process to reduce the error of the Markov model against epidemiological 
reports. The Atkinson ICERs (ICER adjusted by the Atkinson Inequality Index (Atkinson 
1970)) are calculated based on the gained QALYs, total screening, and treatment costs to 
evaluate the screening policies. Hypothetical participants are tested via different policies 
between age 50 and 80. Results show that the annual FOBT between 50 and 80 is cost-
effective and has a higher health disparity compared to no-screening. Prakash et al. 
(2017) developed a micro-simulation model based on Colon Modeling Open Source Tool 
(CMOST) to calculate the optimal timing of colonoscopy tests. The proposed micro-
simulation model calculates the impact of different screening policies and their 
incorporated costs. CMOST models the natural history of CRC providing automated 
calibration of model parameters to meet the epidemiological benchmarks. Their proposed 
natural history model is limited as it includes only early adenomas, advanced adenomas, 
cancer, and direct cancer. A greedy search algorithm is used to calibrate this model. They 
have shown that CRC incidence and mortality rates are reduced most efficiently by 
colonoscopy between ages 56 and 59 while colonoscopy at 59 is the most cost-effective 
screening policy.  
13 
There are a few studies evaluating CRC screening policies with a combination of 
CRC screening tests (Byers et al. 1997; Eisen et al. 2000; Lieberman et al. 2001; Rex et 
al. 2000; Winawer et al. 1997). Telford et al. (2010) developed a probabilistic Markov 
model to estimate the cost-effectiveness of CRC screening policies and to derive the 
optimal screening policy among all available policies. Low-risk polyp and advanced 
adenoma are the two pre-cancer states in their proposed model. The proposed model 
includes localized cancer, regional cancer, and distant cancer which are also divided into 
clinical and preclinical cancers. The model does not include possible adenomatous 
polyps’ regression. No calibration process is described as being used in this study. Ten 
different screening policies are examined using the data from the literature. They 
concluded that all of the ten screening policies are cost-effective. Colonoscopy every 10 
years between 50 and 75 is introduced as the most effective policy as a result of 
significant reduction in CRC incidence and mortality rates. However, annual FIT 
between 50 and 75 is determined as the most cost-effective policy. Frazier (2000) 
developed a model similar to Telford et al.'s (2010) model to assess the cost-effectiveness 
of CRC screening policies in average-risk patients. Pre-cancerous adenomas are divided 
into two levels based on their risk of becoming cancer, low-risk adenoma, and high-risk 
adenoma, and the model is calibrated based on logistic regression methods. Distal and 
proximal parts of the colon are considered separately in this model in order to evaluate 
the performance of the FS more accurately. Follow-up colonoscopy is modeled as well 
for the patient diagnosed with high-risk polyps and positive FS. The comparison is done 
based on ICER, discounted lifetime costs and life expectancy. Annual FOBT from age 50 
to 85 in conjunction with FS every 5 years is shown to be the most cost-effective policy 
14 
in this study.  Sharaf and Ladabaum (2013) used a similar Markov model to explore the 
comparative effectiveness and cost-effectiveness of colonoscopy against FS and other 
CRC screening tests. The natural history model categorizes adenomas into small and 
large adenomas. The model is calibrated and related outputs are validated against several 
trials and studies such as the Minnesota Colon Cancer Control Study and UK Flexible 
Sigmoidoscopy Trial. Calibration methods are not discussed in the published article. 
Symptomatic cancer is included in this model; however, the study lacks modeling 
adenoma regression possibility. Results show higher adherence on FIT tests and 
colonoscopy is shown to be cost-effective versus FS. They concluded that the cost-
effectiveness of colonoscopy versus FS and FIT is dependent on the adherence rate 
associated with colonoscopy. Dinh et al. (2013) developed a simulation model to evaluate 
the cost-effectiveness of multi-modal CRC screening scenarios. The developed model, 
called Archimedes, is a large-scale simulation of human physiology, diseases, 
interventions, and health care systems. The model has separated the natural history into 
three major steps: adenoma development, tumor growth, and cancer symptoms. The CRC 
sub-model of the Archimedes was developed in collaboration with the ACS using 
published epidemiological studies and clinical trials data. The sub model is calibrated 
against several reports including the SEER report although authors have not discussed 
their calibration method in the published article.  Annual or biennial FIT between 50 and 
65 with one time colonoscopy at 66 shown to be cost-effective and comparable with cost-
effective uni-modal policies with favorable impact on resources demands. 
The studies listed above fall short in the level of the details they incorporate in 
modeling adenomatous polyps (pre-cancerous states) due to lack of available data. 
15 
Moreover, some of the available models (Lee and Park 2016; Van Rossum et al. 2011) 
have not simulated multiple adenomatous polyps growths. Natural history model 
validation is another restriction for different studies (Pil et al. 2016; Telford et al. 2010; 
Van Rossum et al. 2011; Vijan et al. 2001). 
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Table ‎2-1: Specifications of the similar studies published in the literature. 
 
Study Model 
Hybrid 
scenarios 
Age range 
for 
screening 
Calibration 
method. 
Adenoma stages Cancer stages 
Adenoma 
regression 
Symptomatic 
cancer 
Source CRC natural history 
relate data 
Best result/final 
conclusion 
Telford et al. 
2010 
Markov Yes 50-75 N/A 
Low risk polyp 
Advanced 
adenoma 
Localized, regional, 
distant (Preclinical 
and clinical) 
No No 
Literature 
SEER 
50-75 Colonoscopy 
every 10 years 
Frazier 2000 Markov Yes 50+ 
Logistic 
regression 
analysis. 
Low risk polyp 
High risk polyp 
Localized, regional, 
distant 
No Yes 
Literature 
SEER 
 
50-85 Annual FOBT, 
FS every 5 years 
Sharaf and 
Ladabaum 
2013 
Markov Yes 50-80 
Methods is not 
discussed 
Small Polyp 
Large Polyp 
 
Localized, regional, 
distant 
No Yes 
Literature 
SEER 
MEDLINE 
Cost-effectiveness is 
depended on the 
adherence rate 
Dinh et al. 
2013 
Archimedes Yes 50-75 
Methods is not 
discussed 
Benign polyp 
Adenomatous 
polyp 
Cancer lesion No Yes 
MEDLINE, Cochrane Database 
of Systematic Reviews, Web of 
Science, PubMed 
50-65 Annual or 
biennial FIT, 
colonoscopy at 66 
Li et al. 2014 Markov No 50-80 
Methods is not 
discussed 
Small, 
medium, large 
Localized, regional, 
distant (Preclinical 
and clinical) 
No Yes 
Clinical data 
Literature 
Colonoscopy interval 
affects cost-
effectiveness 
Vijan et al. 
2007 
Markov No 50-80 N/A 
Low risk polyp 
High risk polyp 
Localized, regional, 
distant (Preclinical 
and clinical) 
No No 
Literature 
SEER 
 
50-80 colonoscopy 
every 10 years 
Pil et al. 2016 Markov No 50+ N/A 
Low-risk polyp 
High-risk polyp 
TNM CRC stage 
classification 
 
 
No No 
Clinical data 
Literature 
Policies are 100 % 
cost-effective for 
males and 97% for 
women 
Van Rossum 
et al. 2011 
Markov No 50-75 N/A 
Advanced 
adenoma 
TNM CRC stage 
classification 
No Yes Clinical data 
One time FIT between 
50 and 75 
Lee and Park 
2016 
Markov No 50-80 
Not mentioned 
N/A 
Polyp 
Early cancer 
Cancer 
Advanced cancer 
No Yes Literature 50-80 Annual FOBT 
Prakash et al. 
2017 
CMOST No NA 
Greedy search 
algorithm  
Early adenoma 
Advanced 
adenoma 
Cancer, direct 
cancer 
Yes Yes 
Literature 
SEER 
MEDLINE 
One time colonoscopy 
between 56 and 59 
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CHAPTER 3 
 
 METHODOLOGY 
 
In this section, the proposed natural history and simulation model modules are 
presented. A detailed Markov framework is developed to model CRC dynamics. The 
details of the proposed Markov model are presented in Section ‎3.1. Simulation models 
characterizing CRC dynamics and possible preventive interventions through CRC 
screening tests are presented in Sections ‎3.2 and ‎3.3, respectively. The detail of the 
calibration process for estimating the age-specific and size-specific transition 
probabilities of the Markov model is provided in Section ‎3.4. 
3.1 CRC Natural History Model 
A Markov chain framework is used to model the CRC natural history. The 
proposed Markov framework is shown in Figure 3-1. The state space of the proposed 
Markov model is              , where state 0 represents no adenoma. Similar to 
MISCAN-Colon model (Loeve 2000), states 1 through 3 represent a diminutive adenoma 
(    ), a medium adenoma (     ) and a large adenoma (     ), 
respectively. States 4 through 6 represents localized, regional, and distant stage cancers, 
respectively. The localized stage represents the stage where the cancer tissue is still 
confined to the primary site. The regional stage represents the stage at which cancer has 
spread to regional lymph nodes. The last stage is the distant stage where the cancer tissue 
has metastasized to the other parts. Based on the TNM classification of malignant tumors 
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system, we assume that localized, regional and distant stages refer to stage I, both stage II 
and III, and stage IV, respectively (National Cancer Institute). The transition probability 
from state   to state   for age group   is denoted by    
 . The transition periods are 
assumed to be one year. Based on a previous study (Rex et al. 1997), and as reflected in 
the Markov model, an adenomatous polyp can grow or regress spontaneously. However, 
once an adenomatous polyp grows to become cancer, the probability of cancer regression 
without a treatment involvement is negligible. For simplification, we assume these rates 
are zero.  The probability of more than one transition from a given state in one year (e.g., 
the growth of a localized cancer from no adenoma state) is considered to be zero due to 
the negligibility of these rates (Sharaf and Ladabaum 2013).  
 
Figure 3-1: Proposed Markov model representing dynamics of adenomatous polyps. 
 We refer to a patient status by a vector of length six, that is               
        , where   ,   , and    represent the number of small, medium, and large 
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adenomatous polyps, respectively, and    ,    , and     represent the number of 
localized cancer (LC), regional cancer (RC), and distant cancer (DC) tissues, 
respectively. For instance, a patient with two small and a large adenomatous polyps and a 
regional cancer tissue is represented by (2, 0, 1, 0, 1, 0). Previous studies have shown that 
the probability of having more than six adenomas/cancer tissues in an individual is 
negligible (Sherer et al. 2013). Therefore, we assume that the maximum number of 
adenomatous polyps/cancer tissues in our model is limited to six (i.e.,            
              ). 
3.2 CRC Natural History Simulation Model 
Figure 3-2 presents a one-year dynamics of the proposed CRC natural history 
simulation model. Simulation of each patient starts at birth (age zero) and the patient is 
followed until he is terminated from the model either due to CRC related death or a 
competing cause of death. Age 100 is considered the simulation terminating age, 
consistent with the maximum life expectancy in the U.S. life table (Arias et al. 2017). 
Note that the maximum number of adenomatous polyps is assumed to be six. Each 
individual adenomatous polyp and cancer tissue dynamics (incidence, progression, and 
regression) are simulated according to the natural history model presented in Figure 3-1. 
At the beginning of each year, the possibility of adding adenomatous polyp(s) is 
evaluated based on adenomatous polyps’ incidence rates and the number of existing 
adenomatous polyps. Existing adenomas may progress or regress during the year as 
captured by the natural history model. We assume that the patient status (number and 
type of adenomas/ cancerous tissues) is updated at the beginning of each year and 
remains the same during the year. 
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Figure 3-2: CRC natural history simulation framework 
3.3 Screening Module Simulation 
Figure 3-3 and Figure 3-4 show the screening and cancer detection simulation 
modules for stool-based and visual CRC screening tests, respectively. As discussed in 
Section ‎3.1, at the beginning of each year the patient status is updated using the natural 
history model. If a screening test is prescribed in a year, the patient undergoes the 
screening test (perfect adherence to the prescribed test). During each year, if CRC is 
present in the patient's body, it may either become symptomatic or be detected through 
screening tests. We assume that any positive result from a stool-based test is followed up 
by a colonoscopy (Figure 3-4) and a biopsy test is performed after receiving a positive 
result on an endoscopic-based test (Figure 3-3). A biopsy may be performed during a 
colonoscopy or any other endoscopic procedures where a gastroenterologist is able to 
retrieve a sample from colon or rectum (Cancer Treatment Centers of America 2015). 
Due to the high sensitivity of biopsy test for cancer in this study, we assume that biopsy 
is a perfect test and reveals the true health status of the patient (Petrelli et al. 1999). It is 
21 
assumed that there is a disutility associated with each test depending on the 
aggressiveness of the test. Patients may receive false positive or false negative results 
depending on the sensitivity and specificity of the prescribed screening test. We assume 
that there is a disutility associated with receiving a false positive result. If not detected 
through screening, the cancer may develop symptoms. Symptomatic cancers are modeled 
using CRC mean sojourn time concept. Cancer sojourn time is defined as the time 
between the onset of preclinical cancer and the point at which cancer becomes 
symptomatic (Zheng and Rutter 2012). Cancer sojourn times are randomly generated 
according to the available distributions at the time of cancer onset. If a CRC case remains 
undetected, either due to false negative results or as a result of no scheduled screening 
test in the period between the cancer onset and the time that the cancer becomes 
symptomatic, cancer will show symptoms at the simulated scheduled time.  The proposed 
simulation model does not incorporate the post-diagnosis procedures (cancer treatment 
and surveillance). Instead, we assume that upon cancer detection, the remaining stage-
specific life expectancy and expected treatment and surveillance costs are accumulated 
and the patient's simulation is terminated. 
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Figure 3-3: Endoscopic-based CRC screening module of the simulation model. 
 
Figure 3-4: Stool-based CRC screening module of the simulation model. 
3.4 Model Calibration Process 
The dynamics of adenomatous polyps (colonic polyps in general) is not well-
studied. In this study, we calibrate the parameters of the proposed simulation model 
(representing a detailed dynamics of pre-cancerous (adenomatous polyps) and post 
cancerous states) using age-specific CRC incidence rates and CRC stage distribution 
reported by the SEER as output measures. The proposed model transition rates are age-
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specific to account for the impact of age as a significant CRC risk factor. SEER report 
(Howlader et al. 2016) includes the number CRC incidences per 100,000 individuals for 
18 different age-groups, including 17 age-groups in 5-year increments for patients 
younger than 85 and an age-group of patients older than 85.  
In this study, a combination of random search and machine learning approaches 
are used for the simulation model calibration. Figure ‎3-5 shows the proposed calibration 
process. Note that the proposed model parameters are age-specific and are estimated in 
five year increments. The calibration process consists of two main phases. In the first 
phase, a random search method is used to find neighborhoods yielding acceptable errors 
below predefined thresholds. In the second phase, machine learning classification 
methods are applied to search the parameter set space to expedite the calibration process. 
 
Figure ‎3-5: An overview of the calibration process. 
For the first output measure, CRC age-specific incidence rates, the weighted sum 
of relative errors of the estimated measures is used to evaluate the goodness of fit of an 
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estimation. Let    and     represent the observed and estimated CRC incidence rates of 
age-group            , respectively. The goodness of fit value for the first output 
measure is 
       
 
   
  
     
  
  Eq. ‎3-1 
where    is the weight associated with the  
   age group. The necessity of using weights 
is discussed in Section ‎3.4.1.  
For the second output measure, CRC stage distribution, the minimum of the sum 
of absolute errors (SAE) as presented in Eq. ‎3-2 is used to select best parameter sets. 
            
   
 Eq. ‎3-2 
where                denotes different CRC stages, and    and    represent the 
observed and estimated ratio of CRC cases in stage  , respectively. 
3.4.1 Characterization of the Training Data  
In the calibration process, the training data includes sets of Markov model 
transition probabilities (to be estimated) as inputs and a set of classes each representing a 
level of deviation from the SEER reported measures as the output. As the two output 
measures (incidence rates and CRC stage distribution) are continuous variables, we 
discretized (labeled) the outputs into different classes in order to apply classification 
machine learning methods. The discretization process occurs through defining envelopes 
and scores for the continued outputs based on the deviation from the observed measures 
reported by the SEER. An envelope is an interval or a set of two intervals defined around 
an observed output measure and represents a level of deviation from the observed 
measure. Let     
          denote the     envelope defined around the observed 
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incidence rate for age-group  , and            denote a predefined threshold controlling 
the tolerance of deviation from the observed incidence rate in the     envelope. The last 
(   ) envelope models an infinite error theoretically. Let    be the score assigned to the 
    envelope representing how close the estimated rates are from the observed rates. 
Table 3-1 represents a SEER incidence rate, hypothetical envelopes surrounding the rate, 
and the associated scores.  
Table 3-1: Schematic envelopes formed around an incidence rate and their associated scores. 
Tolerance Envelope Score 
                                         
                                                                          
… … … 
                                                                          
… … … 
-                                                 
 
Let    denote the final score associated with the estimated incidence rates 
(       ) obtained from the simulation model. The final score of a parameter set is 
calculated as the weighted sum (over all the age-groups) of scores of the envelopes which 
include the estimated incidence rates. Eq. ‎3-3 calculates the final score of a parameter set 
based on the estimated incidence rates. Note that a larger score implies a larger error and 
the goal is to minimize the overall score. Therefore, lower scores must be assigned to the 
envelopes with smaller tolerance. 
            
 
   
    
 
   
 Eq. ‎3-3 
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where     is the Kronecker delta function and is defined in Eq. ‎3-4,    the score 
associated with the     envelope, and    
  
   
 
   
 is the weight associated with age-group 
 . 
      
             
 
 
            
  Eq. ‎3-4 
The length of an envelope is calculated based on the magnitude of the associated 
incidence rates of the corresponding age-group. At younger ages, when the incidence 
rates are lower, the envelopes are smaller. As the patients become older, the envelope 
sizes increase. Therefore, the     envelopes at a younger age-group represents a smaller 
error compared to the counterpart envelope   at older age-group. To account for the 
different error representation of envelopes at different age-groups, envelope scores are 
weighted to enforce more weights on the age-groups with wider envelopes.  
Similarly, envelopes are developed around the observed CRC stage ratios     
with a predefined tolerance           , specifying the envelope's size. Let    
    
      denote the     envelope defined around the actual rate   . 
The final score associated with the estimated ratios, (  ) obtained from the 
simulation model, is calculated as the summation of the scores of the envelopes which 
include the estimated cancer stage ratio, as presented in Eq. ‎3-5. 
            
 
   
 
   
 Eq. ‎3-5 
where     is the Kronecker delta function and is defined similar to Eq. ‎3-4 and it takes 
value 1 if       
 , and 0, otherwise. 
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The final class that a set of parameters belongs to is determined based on the 
maximum value of    and   , i.e.,                 . Note that      is always 
between    and   . Let             , denote the  
   class. Class    is defined as 
parameter sets for which               , where    is the score assigned to the  
   
envelopes. Using the above process, the simulation data is transformed into labeled data. 
A balanced training data set is desirable in machine learning in order to increase 
the accuracy and precision of machine learning methods (Batista et al. 2004). Balance of 
a training data set is a function of tolerances and envelope scores since the final score of a 
parameter set is calculated based on the envelope scores of the age-groups. For example, 
given that we have four envelopes, desired tolerances and scores divide the training data 
into three different classes with each class containing approximately 33% of the data. 
3.4.2 Decision Tree Model 
A Decision Tree (DT) is an inductive learning algorithm consisting of several 
recursive decision rules, arranged hierarchically similar to the structure of a tree (Pradhan 
2013). The algorithm is based on the “divide and conquer” strategy and generates a 
classification tree using the training data/samples. The tree includes internal nodes (    
and    in Figure ‎3-6) and external (        in Figure ‎3-6) nodes. At each internal node, 
a test is applied to one or more attribute values to decide which node to visit next. An 
external node, also known as a terminal node, characterizes the output class.  DT are 
recommended to extract unknown patterns from large data-sets with distinction purposes.  
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Figure ‎3-6: A schematic decision tree. 
In order to train the DT, a training data set is first generated using the simulation 
model. Generated data are labeled using the approach described in Section ‎3.4.1. The DT 
is then trained and validated using the labeled data set. If the trained DT does not meet 
the acceptable level of accuracy, a new set of envelopes and scores will be generated. 
This process is iterated until an acceptable level of accuracy is reached. After the DT is 
trained, random parameter sets are generated to be classified by the trained DT. Note that 
a random parameter set is a set of transition probabilities (without the output measures). 
The DT classifies (labels) the randomly generated parameter sets into different classes. 
Parameter sets that are classified into the best class (with             ) are then fed 
into the simulation model to be evaluated. Among the parameter sets examined by the 
simulation model, the one which gives the smallest errors, calculated using Eq. ‎3-1 and 
Eq. ‎3-2, is selected. If the errors associated with the best data set are less than the 
acceptable thresholds (   and    respectively), the calibration process is completed. 
Otherwise, new parameter sets are randomly generated and the process is repeated until 
an acceptable error level is reached. 
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In summary, the proposed calibration method expedites the calibration process by 
exploiting machine learning tools. Specifically, instead of searching the transition 
probability space through time-consuming simulation model, the DT identifies the 
neighborhoods that are more likely to have the "optimal" parameter sets at a significantly 
faster pace. The simulation is then run only on the parameter sets identified as good 
solutions by the DT.  For example, for 1000 parameter sets, the simulation model 
(simulating 100,000 patients per parameter set) takes over 140 hours. The DT, however, 
classifies the same number of parameter sets in less than a minute.
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CHAPTER 4 
 
MODEL PARAMETER ESTIMATION 
 
The main challenge in the parameter estimation of the proposed model is to 
estimate the Markov model age-specific transition probability matrices. Particularly, the 
proposed model is very complex since it incorporates low level details of adenomas 
dynamics, including regression probabilities. An active learning approach, as discussed in 
Section ‎3.4, is used to estimate these parameters. Section ‎4.1 provides the details of the 
calibration process results for estimation of age-specific transition probabilities. Please 
note that the model is calibrated to represent the U.S. male population. Section ‎4.2 
presents the data sources used for estimation of the remaining parameters. 
4.1 Calibration Results 
Using the normalization constraint in the proposed Markov model, the number of 
the transition probabilities to be estimated for a given age-group is decreased from 15 to 
9. Therefore, given that there are 18 age-groups, the total number of transition 
probabilities to be estimated is 162. 
Using the random search method, at the end of the first phase of the calibration 
process the minimum error achieved for each output measure is 8%. In the second phase, 
three thousand random parameter sets in the neighborhoods of the estimated parameters 
(obtained in the first phase of the calibration process) are generated. The generated 
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parameter sets are then fed into the simulation model to calculate the output measures of 
interest. The result of the simulation model is then used to specify the characteristics of 
the discretization process which includes specifying envelopes and scores and to train the 
classification tool. Note that too many envelopes, and therefore classes, make the model 
more complicated and thereby slower. Moreover, note that we are only interested in the 
class with the smallest error. Therefore, there is no need to make the model more 
complicated by defining too many envelopes. There is no specific rule on what the 
numbers of envelopes, tolerance values and score must be. Therefore, using a trial and 
error approach, different combinations are examined for the model tuning. The results 
implied that setting the number of envelopes to three does not reach the desired accuracy 
and the model does not clearly differentiate the classes. Table ‎4-1 presents the best 
parameter values found in the calibration process. The score associated with the fourth 
envelope is considerably larger than that of the other envelopes to ensure that parameters 
sets with high deviation from the actual output measures in one or more age groups are 
not classified in the first class (with the lowest overall score). 
The classifiers are then trained using 80% of the training data set and validated 
using the remaining 20% of the data. Three different machine learning methods, namely 
Multilayer Perceptron (MLP), Naive Bayes (NB) and Decision Tree (DT) are tested. DT 
model outperformed the other two models in terms of accuracy and precision. We use the 
Gini Index to evaluate splits in the data set when training the DT. The DT reached an 
accuracy of 91%. 
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Table ‎4-1: List of the tolerances and scores obtained in the model tunning process. 
Incidence rate tolerance Stage distribution tolerance Score 
0.1 0.05 0 
0.2 0.1 3 
0.4 0.2 6 
>0.4 >0.2 200 
 
After the DT is trained and validated, new parameter sets are randomly generated 
and classified using the trained model. The parameter sets that are classified in the first 
class with the lowest score then are fed into the simulation model for exact error 
evaluation. Acceptable error threshold for CRC incidence rates (  ) and CRC stage 
distribution (  ) are set to 5% and 1%, respectively. The error threshold for the CRC 
incidence rate is selected to be higher since this error measures the deviation from the 
observed incidence under 18 different age-groups and therefore even a reasonable error in 
each age-group may add up to a big error. The minimum error for the first output 
measure (incidence rate) and second output measure (CRC stage distribution) achieved 
are 3.1% and 0.46%, respectively. Figure ‎4-1 and Figure ‎4-2 show the estimated 
incidence rates and CRC stage distribution, respectively, plotted against the same 
measures reported by the SEER. The estimated age-specific transition probabilities are 
presented in Table A-1 and Table A-2 in ‎APPENDIX A. 
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Figure ‎4-1: Age specific estimated incidence rates using DT (red) and incidence rates 
reported by SEER (blue). 
 
Figure ‎4-2: CRC stage distribution obtained by the calibration model compared with those 
reported by SEER. 
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4.2 Other Parameters 
Table A-6 presents the data sources used for parameter estimations. Natural cause 
and CRC related mortality rates are calculated using SEER cancer statistics review 
(Howlader et al. 2016) and the US life table (Arias et al. 2017). Age and stage specific 
life expectancy of CRC patients are estimated using the MD Anderson CRC survival 
calculator (MD Anderson Cancer Center CRC Survival Calculator 2009). Screening 
specifications are adopted from recently published literature (Erenay et al. 2014; Knudsen 
et al. 2016). Screening costs are the source of most of the disparities in cost-effectiveness 
studies. In order to retrieve the most accurate cost estimates, we adopted the screening 
and treatment costs from most recent published studies to make sure there are no 
significant technology changes. In addition, all costs are adjusted to the calendar year 
2018 dollars by using the Bureau of Labor Statistics Consumer Price Index (Bureau of 
Labor Statistics 2018). The CRC sojourn time is assumed to follow an exponential 
distribution (Loeve 2000) and the mean parameters are adopted from Brenner et al.'s 
(2011) study. 
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Table ‎4-2: Data source and estimated parameters used in the simulation model. 
Parameter Value Reference 
Age-specific precancerous transition 
probabilities   
Table A-1 Sherer et al. 2013  
Age-specific post-cancerous transition 
probabilities   
Table A-2 Macafee et al. 2008  
Age-specific mortality rates  US. Life Table Arias et al. 2017 
CRC localized stage mortality rates 
CRC regional stage mortality rates 
CRC distant stage mortality rates 
0.0542 
0.1677 
0.6469 
Macafee et al. 2008 
Age-specific quality adjusted life year 
<= 44 
45-54 
55-64 
65-74 
75+ 
 
0.91 year 
0.78 year 
0.77 year 
0.75 year 
0.73 year 
Fryback and Lawrence 1997 
Colonoscopy disutility 
FS disutility 
FIT disutility 
FOBT disutility 
11 days 
2 days 
1 days 
1 days 
Erenay et al. 2014 
Mayo clinic 2018 
American Cancer Society 2018 
American Cancer Society 2018 
Stage-specific CRC life expectancy Table A-3 
MD Anderson Cancer Center CRC 
Survival Calculator 2009 
CRC mean sojourn time Table A-4 Brenner et al. 2011 
Screening tests sensitivities Table A-5 Knudsen et al. 2016 
Colonoscopy specificity 
FS specificity 
FIT specificity 
FOBT specificity 
86% 
87% 
89.8% 
92.5% 
Knudsen et al. 2016 
Colonoscopy cost 
FS cost 
FIT cost 
FOBT cost 
$1192.6 
$548.47 
$24.88 
$24.88 
Prakash et al. 2017 
Sharaf and Ladabaum 2013 
Bureau of Labor Statistics 2018 
Treatment costs Table A-6 Joseph 2018 
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CHAPTER 5 
 
NUMERICAL RESULTS 
 
Different screening policies are implemented to a cohort of one hundred thousand 
males. Screenings are applied to the cohort of individuals aged from 50 to 75. The 
screening policies differ in the type of screening tests and screening intervals. A cost-
effectiveness analysis on a broad set of uni-modal and multi-modal CRC screening 
policies is performed. Specifically, we assess 78 different policies including no-
screening, five CRC screening policies recommended by different US health agencies, 
and 72 alternative multi-modal screening policies. The five in-practice screening policies 
analyzed are Colonoscopy at 50, 60 and 70, annual FIT, annual FOBT, FS every 5 years 
and FOBT every 3 years in conjunction with FS every 5 years. FIT, FOBT, colonoscopy, 
and FS are the screening modalities considered in the alternative screening policies. 
Policies are generated by combining policies recommended by the health agencies and 
some recent studies. In the evaluated multi-modal policies, patients undergo two different 
types of tests: a stool-based test and a visual test. Stool-based tests are associated with 
lower cost and are less aggressive compared to visual tests. Visual tests, on the other 
hand, are more sensitive and costly. We assume each year at most one screening test is 
performed on a patient unless the patient receives a positive result and is referred for a 
biopsy. In a year with a confluence of two different screening tests, only the visual test 
(FS or colonoscopy) is used. The frequencies of the tests are selected based on the 
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recommended frequencies by the health agencies and the literature. Stool-based tests are 
prescribed annually or biennially, and FS and colonoscopy are prescribed at 5-year and 
10-year frequencies, respectively. The policies investigated in this study are listed in 
Table 5-1. 
All 78 policies considered in this study are represented in Figure 5-1. The blue 
points are the “inefficient” or "dominated" policies, or the policies that are each 
dominated by other screening policy(ies) with a higher QALYs and lower cost. The 
identified “efficient" or "dominant" and in-practice policies are presented in green and 
red, respectively. FOBT biennially in conjunction with one time Colonoscopy at 60, 
FOBT biennially along with one time Colonoscopy at 50, FIT biennially in conjunction 
with two times FS at 60 and 65, FIT biennially with one time Colonoscopy at 65, 
Colonoscopy at 50, 60 and 70, FOBT biennially along with two times Colonoscopy at 55 
and 65, FOBT annually with 2 times FS at 70 and 75,  FOBT annually in conjunction 
with FS at 50,55 and FIT biennially along with FS every 5 years are the nine identified 
dominant policies. The structure of the identified dominant policies show that undergoing 
endoscopic-based tests between age 55 and 65 benefits the patients. In addition, 
prescribing stool-based tests for the patients biennially is shown to be more cost-effective 
as suggested by 6 of the identified dominant policies. Prescribing stool-based tests 
annually seems to unnecessarily increase the expected cost while it does not significantly 
affect the expected QALYs. As the results show, for each in-practice policy, there is an 
alternative policy that results in higher QALYs with the same or a lower cost of the in-
practice policy. For instance, consider the in-practice policy of FS every 5 years. This 
policy yields the highest expected QALYs (67.05 years), with an associated expected cost 
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of $3,762, among the in-practice polices. However, the alternative policy of FOBT 
annually, in conjunction with FS at 70 and 75 yields both higher expected QALYs (67.06 
years) and lower expected cost ($3,684). The results show all the 77 policies evaluated in 
this study benefit the patients through increased QALYs and decreased CRC mortality 
compared to no screening policy. In most cases, combining stool-based tests with visual 
tests will benefit patients with higher life expectancy and lower expected cost. Multi-
modal policies are associated with higher reduction rates in CRC incidence and mortality 
compared with uni-modal scenarios. 
 
Figure 5-1: Efficient frontier versus the in-practice policies. 
In order to evaluate the performance of different CRC screening policies, 
incremental cost-effectiveness ratio (ICER) is calculated. ICER is calculated as the 
expected cost difference per expected QALYs difference for every 2 consecutive policies 
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while all screening policies are sorted in expected QALYs in an increasing order. Let    
and     denote two consecutive policies with associated        and       , 
respectively and              . Eq. ‎5-1 calculates the ICER value when comparing 
policies    and    and represents the ratio of the additional cost that must be paid under 
policy    for one additional unit of QALYs when compared with policy   . A negative 
value for        represents that policy    is dominated by policy    since policy    is 
associated with higher expected cost and lower expected QALYs. ICER for dominant 
screening policies is calculated as the cost difference per QALY gained relative to the 
nearest efficient frontier policy (Dinh et al. 2013). 
        
                             
                           
 Eq. ‎5-1 
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Table 5-1: Cost, QALYs, and ICER associated with the investigated policies.  
Policy QALYs Cost ICER Policy QALYs Cost ICER 
No screening 66.61 $1,306 NA 
FOBT annually, 
Colonoscopy at 60 
66.99 $3,870 Dominated 
FIT annually, 
Colonoscopy at 50, 
60, 70 
66.91 $6,221 Dominated 
FOBT biennially, 
Colonoscopy at 60 
66.99 $2,634 $3,486 
FIT annually, FS at 
55,60 
66.91 $4,342 Dominated 
FOBT biennially, 
Colonoscopy at 65, 75 
66.99 $3,546 Dominated 
FIT biennially, 
Colonoscopy at 60, 70 
66.91 $3,718 Dominated 
FIT annually, 
Colonoscopy at 60 
67.00 $4,505 Dominated 
FOBT annually, 
Colonoscopy at 55, 
65, 75 
66.91 $5,480 Dominated 
FIT biennially, 
Colonoscopy at 70 
67.00 $2,934 Dominated 
FIT annually, FS at 
70, 75 
66.92 $4,273 Dominated 
FIT biennially, 
Colonoscopy at 50, 
60, 70 
67.00 $4,591 Dominated 
FIT annually, FS at 
60, 65 
66.93 $4,328 Dominated 
FOBT annually, FS at 
55, 60 
67.00 $3,776 Dominated 
FIT biennially, 
Colonoscopy at 75 
66.93 $3,034 Dominated 
FOBT annually, 
Colonoscopy at 50 
67.00 $3,886 Dominated 
FOBT biennially, FS 
at 55, 60 
66.93 $2,748 Dominated 
FOBT biennially, 
Colonoscopy at 55 
67.00 $2,744 Dominated 
FIT annually, 
Colonoscopy at 55, 
65, 75 
66.94 $6,129 Dominated 
FOBT every 3 years , 
FS every 5 years 
67.01 $3,245 Dominated 
FIT biennially, 
Colonoscopy at 60 
66.94 $2,941 Dominated 
FOBT annually, FS at 
60, 65 
67.01 $3,735 Dominated 
FOBT annually, 
Colonoscopy at 60, 70 
66.94 $4,666 Dominated 
FOBT annually, FS 
every 5 years 
67.01 $5,101 Dominated 
FOBT annually, 
Colonoscopy at 65, 75 
66.94 $4,559 Dominated 
FOBT annually, 
Colonoscopy at 75 
67.01 $3,755 Dominated 
FOBT annually, 
Colonoscopy at 50, 
60, 70 
66.94 $5,582 Dominated FIT annually 67.02 $3,680 Dominated 
FIT annually, 
Colonoscopy at 55, 65 
66.95 $5,391 Dominated 
FIT annually, 
Colonoscopy at 65 
67.02 $4,479 Dominated 
FIT annually, FS 
every 5 years 
66.95 $5,610 Dominated 
FIT biennially, 
Colonoscopy at 55 
67.02 $3,085 Dominated 
FIT biennially, 
Colonoscopy at 55, 
65, 75 
66.95 $4,852 Dominated 
FOBT annually, 
Colonoscopy at 50, 60 
67.02 $4,750 Dominated 
FIT biennially, FS at 
55, 60 
66.95 $3,016 Dominated 
FOBT biennially, FS 
at 50,55 
67.02 $2,781 Dominated 
FIT biennially, FS at 
65, 70 
66.95 $2,963 Dominated 
FOBT biennially, FS 
every 5 years 
67.02 $4,183 Dominated 
FOBT biennially, FS 
at 70, 75 
66.95 $2,682 Dominated 
FOBT biennially, 
Colonoscopy at 50 
67.02 $2,692 $2,031 
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Policy QALYs Cost ICER Policy QALYs Cost ICER 
FIT annually, 
Colonoscopy at 75 
66.96 $4,388 Dominated 
FOBT biennially, 
Colonoscopy at 65 
67.02 $2,737 $177,503 
FIT annually, 
Colonoscopy at 60, 70 
66.96 $5,304 Dominated 
FOBT biennially, 
Colonoscopy at 60, 70 
67.02 $3,424 Dominated 
FOBT biennially, 
Colonoscopy at 70 
66.96 $2,682 Dominated 
FOBT biennially, 
Colonoscopy at 50, 
60, 70 
67.02 $4,306 Dominated 
FOBT biennially, 
Colonoscopy at 75 
66.96 $2,724 Dominated 
FIT annually, 
Colonoscopy at 50 
67.03 $4,502 Dominated 
FIT annually, FS at 
50, 55 
66.97 $4,364 Dominated 
FIT biennially, FS at 
50, 55 
67.03 $3,064 $332,458 
FOBT annually, 
Colonoscopy at 55 
66.97 $3,855 Dominated 
FIT biennially, FS at 
60, 65 
67.03 $2,985 $22,856 
FIT annually, 
Colonoscopy at 55 
66.98 $4,492 Dominated 
FOBT annually, 
Colonoscopy at 65 
67.03 $3,820 Dominated 
FIT annually, 
Colonoscopy at 70 
66.98 $4,441 Dominated 
FOBT biennially, 
Colonoscopy at 55, 
65, 75 
67.03 $4,517 Dominated 
FIT annually, FS at 
65, 70 
66.98 $4,312 Dominated FOBT annually 67.04 $3,100 Dominated 
FIT biennially, 
Colonoscopy at 50 
66.98 $2,974 Dominated 
FIT biennially, 
Colonoscopy at 65 
67.04 $3,070 $834 
FIT biennially, 
Colonoscopy at 50, 60 
66.98 $3,803 Dominated 
FIT biennially, 
Colonoscopy at 55, 65 
67.04 $4,023 Dominated 
FIT biennially, 
Colonoscopy at 65, 75 
66.98 $3,883 Dominated 
FOBT annually, 
Colonoscopy at 70 
67.04 $3,804 Dominated 
FOBT annually, FS at 
65, 70 
66.98 $3,726 Dominated 
FOBT biennially, 
Colonoscopy at 50, 60 
67.04 $3,528 Dominated 
FOBT annually, 
Colonoscopy at 55, 65 
66.98 $4,714 Dominated 
Colonoscopy at 50, 
60, 70 
67.05 $3,341 $44,760 
FOBT biennially, FS 
at 60, 65 
66.98 $2,747 Dominated FS every 5 years 67.05 $3,762 Dominated 
FOBT biennially, FS 
at 65, 70 
66.98 $2,718 Dominated 
FOBT annually, FS at 
70, 75 
67.06 $3,684 $4,387 
FIT annually, 
Colonoscopy at 50, 60 
66.99 $5,397 Dominated 
FOBT biennially, 
Colonoscopy at 55, 65 
67.06 $3,682 $22,824 
FIT annually, 
Colonoscopy at 65, 75 
66.99 $5,226 Dominated 
FOBT annually, FS at 
50, 55 
67.08 $3,781 $6,859 
FIT biennially, FS at 
70, 75 
66.99 $2,947 Dominated 
FIT biennially, FS 
every 5 years 
67.09 $4,442 $43,183 
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Table 5-1 presents all the policies investigated in this study with their associated 
QALYs, cost and ICER. Willingness to pay (WTP) is defined as the maximum price at or 
below which the patient (consumer) will buy a service (product) (Miller et al. 2011). At 
$50,000 WTP threshold (Sharaf and Ladabaum 2013), among the 11 dominant policies, 9 
policies are cost-effective out of which 8 policies are multi-modal. Multi-modal policies 
are also associated with lower ICER compared with the identified cost-effective uni-
modal policy (Colonoscopy at 50, 60 and 70).  
The performance of the in-practice policies and best alternative policies in terms 
of expected QALYs, incidence reduction, and mortality reduction, when compared with 
no screening policy are compared in Table 5-2. Among the in-practice policies 
colonoscopy at 50, 60 and 70 outperforms other policies in terms of expected QALYs 
(67.05), incidence and mortality reduction (86.5% and 89.4% respectively). Comparing 
this policy with the alternative policies, FIT biennially in conjunction with FS every 5 
years benefits the patients with higher expected QALYs (67.09). FOBT biennially along 
with three times colonoscopy at 50, 60 and 70 serves the patients with higher incidence 
reduction (88.6%) and FIT annually, colonoscopy at 55, 65 and 75 benefits patients with 
higher mortality reduction (93%) compared to the best identified in-practice policy. 
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Table 5-2: In-practice policies and best identified alternative policies in terms of the expected 
QALYs, incidence reduction, and mortality reduction - number in parentheses represent 
confidence intervals (CI). 
 
Policy 
Expected 
QALYs 
Incidence 
Reduction 
Mortality 
Reduction 
In
-p
ra
ct
ic
e 
No screening 
66.61 
(66.59,66.63) - - 
FIT annually 
67.02 
(67.00,67.04) 69.8% 85.4% 
FOBT annually 
67.04 
(67.01,67.07) 60.4% 80.1% 
FS every 5 years 
67.05 
(67.03,67.07) 71.1% 81.1% 
FOBT every 3 years, FS every 5 years 
67.01 
(66.99,67.03) 62.7% 79.0% 
Colonoscopy at 50, 60 and 70 
67.05 
(67.02,67.07) 86.5% 89.4% 
A
lt
er
n
a
ti
v
e FIT biennially, FS every 5 years 
67.09 
(67.07,67.11) 75.8% 87.1% 
FOBT biennially, Colonoscopy at 50, 60, 
70 
67.02 
(67.00,67.04) 88.6% 91.9% 
FIT annually, Colonoscopy at 55, 65, 75 
66.94 
(66.91,66.97) 87.1% 93.0% 
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CHAPTER 6 
 
CONCLUSION 
 
As implied by multiple health agencies, currently there is no consensus on which 
CRC screening policy is the most effective. In this study, we adopted a Markov chain 
framework to model CRC natural history. We used Monte Carlo simulation approach to 
model the CRC dynamics and quantify the effectiveness of CRC preventive 
interventions. Using active learning, specifically a decision tree, we devised an 
innovative calibration process to estimate the parameters of the detailed proposed natural 
history model, i.e., age-specific and size-specific adenoma progression and regression 
rates as well as age-specific CRC progression rates. This method calibrates the proposed 
simulation model through a more efficient and faster process compared to other methods 
used in the literature such as trial and error, random sampling, and grid search. 
A cohort of 100,000 males is simulated under 78 different CRC screening policies 
using the calibrated model. A cost-effectiveness analysis is performed on different 
screening policies. Screening policies are compared in terms of the associated expected 
screening and treatment cost, expected QALYs, and reduction in the CRC incidence and 
mortality rates. The numerical analysis results show that in most cases, combining stool-
based tests with visual tests will benefit patients with higher life expectancy and lower 
expected cost. Multi-modal policies are associated with higher reduction rates in CRC 
incidence and mortality compared with uni-modal scenarios. Among the nine identified 
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dominant policies under $50,000 WTP threshold, eight policies are multi-modal. Multi-
modal policies are also associated with lower ICER compared with the identified cost-
effective uni-modal policy. 
This study has several limitations. First, using multiple data sources for parameter 
estimation introduces some potential sources of errors. Screening and treatment costs are 
usually difficult to estimate due to the wide estimation variation in the literature. Second, 
a discretization approach is taken in this study when calibrating the model through the 
DT training as DT is a classification approach.  The discretization introduces some errors 
due to classifying different errors in one class. Employing prediction models that can 
work with continuous variables, and thereby avoiding discretization, would result in 
eliminating this error in the calibration process. This study is limited to male population 
and incorporates age as the only CRC risk factor. However, other risk factors such as 
gender and family history, etc., need to be taken into account for more precise disease 
modeling. A risk stratification model which takes into account patient-specific risk 
factors and recommend policies accordingly would be a possible future direction. 
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APPENDIX A  
 
MODEL PARAMETERS USED IN THE SIMULATION MODEL 
Table A-1: Age-specific pre-cancer transition probabilities  
Age group                                             
1-4 0.992 0.008 0.008 0.966 0.026 0.013 0.960 0.026 0.005 0.975 0.020 
5-9 0.999 0.001 0.004 0.991 0.004 0.008 0.988 0.005 0.003 0.994 0.003 
10-14 0.996 0.004 0.005 0.983 0.012 0.008 0.979 0.013 0.003 0.988 0.010 
15-19 0.996 0.004 0.003 0.985 0.012 0.006 0.982 0.012 0.002 0.989 0.009 
20-24 0.996 0.004 0.004 0.982 0.014 0.007 0.979 0.015 0.002 0.987 0.011 
25-29 0.996 0.004 0.004 0.982 0.014 0.007 0.978 0.015 0.003 0.986 0.011 
30-34 0.993 0.007 0.005 0.972 0.023 0.008 0.968 0.024 0.003 0.979 0.018 
35-39 0.990 0.010 0.006 0.960 0.034 0.010 0.955 0.035 0.004 0.970 0.026 
40-44 0.994 0.006 0.006 0.975 0.019 0.011 0.970 0.019 0.004 0.982 0.014 
45-49 0.989 0.011 0.009 0.953 0.038 0.016 0.946 0.038 0.006 0.965 0.029 
50-54 0.990 0.010 0.011 0.957 0.032 0.018 0.949 0.033 0.007 0.969 0.025 
55-59 0.990 0.010 0.009 0.958 0.032 0.016 0.951 0.033 0.006 0.969 0.025 
60-64 0.989 0.011 0.009 0.955 0.035 0.016 0.948 0.036 0.006 0.967 0.027 
65-69 0.987 0.013 0.012 0.944 0.044 0.020 0.934 0.045 0.008 0.958 0.034 
70-74 0.988 0.012 0.010 0.951 0.039 0.018 0.943 0.040 0.007 0.964 0.030 
75-79 0.988 0.012 0.011 0.948 0.041 0.018 0.940 0.042 0.007 0.961 0.032 
80-84 0.988 0.012 0.011 0.948 0.041 0.019 0.939 0.042 0.007 0.962 0.031 
85+ 0.990 0.010 0.010 0.957 0.033 0.017 0.950 0.034 0.006 0.968 0.025 
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Table A-2: Age-specific cancer states transiotion probabilities. 
Age group                 
1-4 0.710 0.290 0.581 0.419 
5-9 0.709 0.291 0.580 0.420 
10-14 0.701 0.299 0.580 0.420 
15-19 0.695 0.305 0.576 0.424 
20-24 0.694 0.306 0.576 0.424 
25-29 0.694 0.306 0.576 0.424 
30-34 0.692 0.308 0.571 0.429 
35-39 0.687 0.313 0.568 0.432 
40-44 0.686 0.314 0.568 0.432 
45-49 0.686 0.314 0.563 0.437 
50-54 0.686 0.314 0.545 0.455 
55-59 0.686 0.314 0.553 0.447 
60-64 0.684 0.316 0.549 0.451 
65-69 0.685 0.315 0.548 0.452 
70-74 0.685 0.315 0.547 0.453 
75-79 0.674 0.326 0.541 0.459 
80-84 0.674 0.326 0.539 0.461 
85+ 0.670 0.330 0.539 0.461 
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Table A-3: Stage-specific life expectancy of CRC patients. 
Age Localized Regional Distant Age Localized Regional Distant 
1 64.76 50.41 5.32 51 23.06 17.00 1.97 
2 63.95 49.81 5.25 52 22.35 16.49 1.66 
3 63.10 49.19 5.23 53 21.63 15.96 1.52 
4 62.31 48.62 5.23 54 20.89 15.41 1.40 
5 61.49 48.00 5.21 55 20.18 14.87 1.36 
6 60.66 47.34 5.21 56 19.44 14.38 1.10 
7 59.85 46.70 5.19 57 18.67 13.79 0.73 
8 58.99 46.02 5.17 58 17.86 13.16 0.71 
9 58.08 45.23 5.12 59 17.01 12.43 0.65 
10 57.12 44.30 4.52 60 16.06 11.52 0.63 
11 56.32 43.62 4.51 61 15.42 11.03 0.60 
12 55.51 43.02 4.46 62 14.80 10.62 0.58 
13 54.66 42.41 4.44 63 14.17 10.17 0.56 
14 53.87 41.83 4.43 64 13.54 9.76 0.55 
15 53.06 41.21 4.42 65 12.88 9.30 0.54 
16 52.23 40.55 4.42 66 12.23 8.87 0.54 
17 51.42 39.91 4.40 67 11.54 8.38 0.52 
18 50.56 39.24 4.38 68 10.78 7.80 0.51 
19 49.66 38.45 4.33 69 9.96 7.11 0.50 
20 48.69 37.52 3.73 70 9.02 6.21 0.50 
21 47.91 36.85 3.72 71 8.56 5.95 0.47 
22 47.12 36.26 3.66 72 8.12 5.67 0.36 
23 46.28 35.66 3.64 73 7.65 5.36 0.34 
24 45.49 35.09 3.64 74 7.19 5.08 0.28 
25 44.69 34.48 3.62 75 6.71 4.75 0.26 
26 43.87 33.82 3.62 76 6.20 4.44 0.25 
27 43.06 33.19 3.60 77 5.63 4.07 0.25 
28 42.21 32.52 3.58 78 5.01 3.62 0.24 
29 41.31 31.73 3.54 79 4.26 3.02 0.23 
30 40.34 30.80 2.94 80 3.36 2.18 0.22 
31 39.57 30.14 2.93 81 3.25 2.12 0.21 
32 38.78 29.55 2.88 82 3.11 2.02 0.19 
33 37.94 28.95 2.86 83 2.80 1.98 0.13 
34 37.16 28.38 2.85 84 2.62 1.91 0.13 
35 36.36 27.77 2.83 85 2.42 1.84 0.08 
36 35.54 27.12 2.83 86 2.17 1.75 0.06 
37 34.74 26.49 2.81 87 1.81 1.63 0.06 
38 33.89 25.82 2.79 88 1.61 1.44 0.05 
39 32.99 25.03 2.75 89 1.29 1.06 0.04 
40 32.02 24.10 2.28 90 0.83 0.69 0.04 
41 31.26 23.45 2.15 91 0.82 0.65 0.04 
42 30.48 22.88 2.14 92 0.78 0.58 0.04 
43 29.66 22.29 2.10 93 0.72 0.58 0.03 
44 28.90 21.73 2.07 94 0.66 0.51 0.02 
45 28.11 21.13 2.06 95 0.63 0.47 0.02 
46 27.30 20.49 2.05 96 0.56 0.45 0.01 
47 26.51 19.87 2.05 97 0.56 0.40 0.01 
48 25.66 19.20 2.03 98 0.52 0.36 0.01 
49 24.77 18.42 2.01 99 0.48 0.34 0.01 
50 23.81 17.49 2.00 100 0.27 0.31 0.01 
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Table A-4: Age-specific mean sojourn time. 
Age Mean Sojourn Time (years) 
1-59 5.5 
60-64 5.2 
65-69 4.7 
70-74 4.9 
75-79 5.0 
80-100 5.5 
 
 
Table A-5: Screening sensitivities. 
 Colonoscopy FS FOBT FIT 
Small adenoma 0.75 0.75 N/A N/A 
Medium adenoma 0.85 0.85 N/A N/A 
Large adenoma 0.95 0.95 N/A N/A 
CRC 0.95 0.95 0.70 0.74 
 
 
Table A-6: CRC stage-specific treatment costs. 
Stage Initial cost (Year 1) Surveillance Costs (Years 2-5) 
Localized $20,247 $1,305 
Regional $26,008 $2,345 
Distant $30,085 $15,057 
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APPENDIX B  
 
PROGRAMMING CODE OF THE MODEL 
 
#library(xlsx) 
#list of policies 
Policies<-matrix(0,100,81) 
Policies[c(50:75),2]<-3 
Policies[c(50,60,70),3]<-1 
Policies[seq(50,75,5),4]<-4 ; Policies[seq(50,75,3),4]<-3 
Policies[c(45:75),5]<-2 
Policies[c(45:75),6]<-3 
Policies[c(45,55,65,75),7]<-1 
Policies[seq(45,75,5),8]<-4 
Policies[c(50:75),9]<-2 
 
Policies[seq(50,75,1),10]<-2 ; Policies[50,10]<-1 
Policies[seq(50,75,1),11]<-2 ; Policies[55,11]<-1 
Policies[seq(50,75,1),12]<-2 ; Policies[60,12]<-1 
Policies[seq(50,75,1),13]<-2 ; Policies[65,13]<-1 
Policies[seq(50,75,1),14]<-2 ; Policies[70,14]<-1 
Policies[seq(50,75,1),15]<-2 ; Policies[75,15]<-1 
Policies[seq(50,75,1),16]<-2 ; Policies[c(50,60),16]<-1 
Policies[seq(50,75,1),17]<-2 ; Policies[c(55,65),17]<-1 
Policies[seq(50,75,1),18]<-2 ; Policies[c(60,70),18]<-1 
Policies[seq(50,75,1),19]<-2 ; Policies[c(65,75),19]<-1 
Policies[seq(50,75,1),20]<-2 ; Policies[seq(50,75,10),20]<-1 
Policies[seq(50,75,1),21]<-2 ; Policies[seq(55,75,10),21]<-1 
 
Policies[seq(50,75,1),22]<-2 ; Policies[c(50,55),22]<-4 
Policies[seq(50,75,1),23]<-2 ; Policies[c(55,60),23]<-4 
Policies[seq(50,75,1),24]<-2 ; Policies[c(60,65),24]<-4 
Policies[seq(50,75,1),25]<-2 ; Policies[c(65,70),25]<-4 
Policies[seq(50,75,1),26]<-2 ; Policies[c(70,75),26]<-4 
Policies[seq(50,75,1),27]<-2 ; Policies[seq(50,75,5),27]<-4 
 
Policies[seq(50,75,2),28]<-2 ; Policies[50,28]<-1 
Policies[seq(50,75,2),29]<-2 ; Policies[55,29]<-1 
Policies[seq(50,75,2),30]<-2 ; Policies[60,30]<-1 
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Policies[seq(50,75,2),31]<-2 ; Policies[65,31]<-1 
Policies[seq(50,75,2),32]<-2 ; Policies[70,32]<-1 
Policies[seq(50,75,2),33]<-2 ; Policies[75,33]<-1 
Policies[seq(50,75,2),34]<-2 ; Policies[c(50,60),34]<-1 
Policies[seq(50,75,2),35]<-2 ; Policies[c(55,65),35]<-1 
Policies[seq(50,75,2),36]<-2 ; Policies[c(60,70),36]<-1 
Policies[seq(50,75,2),37]<-2 ; Policies[c(65,75),37]<-1 
Policies[seq(50,75,2),38]<-2 ; Policies[seq(50,75,10),38]<-1 
Policies[seq(50,75,2),39]<-2 ; Policies[seq(55,75,10),39]<-1 
 
Policies[seq(50,75,2),40]<-2 ; Policies[c(50,55),40]<-4 
Policies[seq(50,75,2),41]<-2 ; Policies[c(55,60),41]<-4 
Policies[seq(50,75,2),42]<-2 ; Policies[c(60,65),42]<-4 
Policies[seq(50,75,2),43]<-2 ; Policies[c(65,70),43]<-4 
Policies[seq(50,75,2),44]<-2 ; Policies[c(70,75),44]<-4 
Policies[seq(50,75,2),45]<-2 ; Policies[seq(50,75,5),45]<-4 
 
Policies[seq(50,75,1),46]<-3 ; Policies[c(50,55),46]<-4 
Policies[seq(50,75,1),47]<-3 ; Policies[c(55,60),47]<-4 
Policies[seq(50,75,1),48]<-3 ; Policies[c(60,65),48]<-4 
Policies[seq(50,75,1),49]<-3 ; Policies[c(65,70),49]<-4 
Policies[seq(50,75,1),50]<-3 ; Policies[c(70,75),50]<-4 
Policies[seq(50,75,1),51]<-3 ; Policies[seq(50,75,5),51]<-4 
 
Policies[seq(50,75,1),52]<-3 ; Policies[50,52]<-1 
Policies[seq(50,75,1),53]<-3 ; Policies[55,53]<-1 
Policies[seq(50,75,1),54]<-3 ; Policies[60,54]<-1 
Policies[seq(50,75,1),55]<-3 ; Policies[65,55]<-1 
Policies[seq(50,75,1),56]<-3 ; Policies[70,56]<-1 
Policies[seq(50,75,1),57]<-3 ; Policies[75,57]<-1 
Policies[seq(50,75,1),58]<-3 ; Policies[c(50,60),58]<-1 
Policies[seq(50,75,1),59]<-3 ; Policies[c(55,65),59]<-1 
Policies[seq(50,75,1),60]<-3 ; Policies[c(60,70),60]<-1 
Policies[seq(50,75,1),61]<-3 ; Policies[c(65,75),61]<-1 
Policies[seq(50,75,1),62]<-3 ; Policies[seq(50,75,10),62]<-1 
Policies[seq(50,75,1),63]<-3 ; Policies[seq(55,75,10),63]<-1 
 
Policies[seq(50,75,2),64]<-3 ; Policies[c(50,55),64]<-4 
Policies[seq(50,75,2),65]<-3 ; Policies[c(55,60),65]<-4 
Policies[seq(50,75,2),66]<-3 ; Policies[c(60,65),66]<-4 
Policies[seq(50,75,2),67]<-3 ; Policies[c(65,70),67]<-4 
Policies[seq(50,75,2),68]<-3 ; Policies[c(70,75),68]<-4 
Policies[seq(50,75,2),69]<-3 ; Policies[seq(50,75,5),69]<-4 
 
Policies[seq(50,75,2),70]<-3 ; Policies[50,70]<-1 
Policies[seq(50,75,2),71]<-3 ; Policies[55,71]<-1 
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Policies[seq(50,75,2),72]<-3 ; Policies[60,72]<-1 
Policies[seq(50,75,2),73]<-3 ; Policies[65,73]<-1 
Policies[seq(50,75,2),74]<-3 ; Policies[70,74]<-1 
Policies[seq(50,75,2),75]<-3 ; Policies[75,75]<-1 
Policies[seq(50,75,2),76]<-3 ; Policies[c(50,60),76]<-1 
Policies[seq(50,75,2),77]<-3 ; Policies[c(55,65),77]<-1 
Policies[seq(50,75,2),78]<-3 ; Policies[c(60,70),78]<-1 
Policies[seq(50,75,2),79]<-3 ; Policies[c(65,75),79]<-1 
Policies[seq(50,75,2),80]<-3 ; Policies[seq(50,75,10),80]<-1 
Policies[seq(50,75,2),81]<-3 ; Policies[seq(55,75,10),81]<-1 
 
 
SCRES<-matrix(0,81,22) #scenario matrix that has each scenario 
 
#for (h in c(1:1)) { #for one scenario 
for (h in c(41:81)) { #policy index 
  Scenario<-Policies[,h] # selecting the scenario  
 
 
t<-1 #number of  
 
load(file ="C:\\Users\\amirhosein.fouladi\\Dropbox\\LA 
Tech\\Research\\Dessertation\\ACL\\Scenarios\\BRates20205000-4.RData") #importing 
the set of parameters 
dim(BRates2020) 
 
#################Variables for calibration process 
BERROR<-matrix(0,t,1) # sum of errors between seer and estimated incidence rates 
BMSERROR<-matrix(0,t,1) #sum squared error recorder between seer and estimated 
incidence rates 
BIGRES<-matrix(0,t,18) # estimated incidence rates 
BDIF<-matrix(0,t,18) # difference between each estimated and actual incidence rates 
################################################## 
 
SEER_Males<-
matrix(c(0,0,0,0.4,1.3,2.5,5.3,9.2,17.4,32.1,61.9,76.1,106.7,153.1,205.4,248.3,301.7,342.
7),18,1,dimnames = list( 
                            c("0-4","5-9","10-14","15-19","20-24","25-29","30-34","35-39","40-
44","45-49","50-54","55-59","60-64","65-69","70-74","75-79","80-84","85+"),"Males")) 
#SEER reported incidence rates 
 
 
GDR<-
(matrix(c(5498,419,283,210,183,151,131,114,98,83,75,84,120,189,284,384,486,600,726,
856,990, 
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1112,1203,1254,1277,1291,1309,1326,1348,1372,1399,1426,1454,1485,1521,1573,1642,
1723, 
              
1813,1914,2027,2164,2332,2542,2795,3068,3366,3716,4116,4548,4989,5435,5901,6401,
6942, 
              
7527,8140,8771,9406,10051,10736,11478,12273,13128,14057,15076,16204,17483,1892
3,20533, 
              
22439,24653,27135,29737,32404,35321,38796,42852,47377,52749,58353,64396,71496,
79699,88491, 
              
97689,109336,122073,135933,150930,167061,184300,202596,221873,242028,262931,2
84431,306354, 
              328515,350719),100,1))/1000000 #general death rates 
 
CDR<-
(matrix(c(rep(0,4),rep(c(0,0,0,0.2,0.5,1.2,2.5,4.7,8.8,15.4,23.5,35.2,48.8,70.6,99.5,137.3,
213.4,213.4,213.4),each = 5),213.4),100,1))/10000 #CRC death rates 
 
DR<-GDR-CDR #death rates based om any causes but CRC 
 
ASDR<-matrix(c(rep(.0542,100),rep(0.1677,100),rep(0.6469,100)),100,3) #stage specific 
CRC death rates 
 
Utilities<-matrix(c(rep(.91,44),rep(c(.78,.77,.75),each=10),rep(0.73,26)),100,1,dimnames 
= list( 
  c(1:100),c("Healthy State Life Expectancy")))  #Healthy State Life Expectancy 
 
Disutilities<-matrix(c(0.0301,0.0027,0.0027,0.0055),4,1,dimnames = 
list(c("Colonoscopy","FIT","FOBT","FS"),"Disutilities")) #test disutilities 
 
DQ<-read.csv("C:\\Users\\amirhosein.fouladi\\Dropbox\\LA Tech\\Research\\CRC-
Simulation files\\Excel Files\\MD Anderson.csv",header = TRUE) # stage specific age 
specific CRC life expectancy 
 
TSen<-
matrix(c(c(.75,.85,.95,.95),.076,.076,.238,.74,.075,.124,.239,.7,.75,.85,.95,.95),4,4,dimna
mes = 
list(c("Dimunitive","Medium","Large","CRC"),c("Colonoscopy","FIT","FOBT","FS"))) 
# Test sensitivities 
 
TSpec<-matrix(c(.86,.898,.925,.87),4,1,dimnames = 
list(c("Colonoscopy","FIT","FOBT","FS"),"Specifity")) # test specificity 
FSF<-matrix(c(1,1,1,1),1,4) #a matrix to disable a test in ascenario (for testing the code) 
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SojT<-matrix(c(rep(5.5,54),rep(c(5.5,5.2,4.7,4.9,5),each=5),rep(5.5,21)),100,1,dimnames 
= list( 
  c(1:100),c("Sojourn Time")))  #mean Sojourn time 
 
##Cost information 
 
Price<-matrix(c(1192.6,24.88,24.88,548.47),4,1,dimnames = 
list(c("Colonoscopy","FIT","FOBT","FS"),"Price")) # test prices 
 
TRC<-
matrix(c(20247.20,1305.04,26007.5,2346.72,30085.20,15057,24544.13,1576.24),2,4,dim
names = list(c("Initial","Surveillance"),c("Local","Regional","Distant","Weighted 
Average"))) #Treatment cost 
 
########################################################################
################### 
 
for(x in c(1:t)){#parameter set index  
   
CC<-matrix(0,100,1) #new cancer cases 
 
DC<-matrix(0,100,1) #death cases 
 
AC<-matrix(0,100,1) #alive cancer cases 
 
Rates<-BRates2020[,,4250] # importing different rates from an array  
#############################  
K<-100000 # of patients 
n<-7 #maximum number of adenomas (one fewer than n) 
###################################### 
BQALYs<-matrix(0,K,1) #QALYs recorde 
BCosts<-matrix(0,K,1) # costs recorde 
CQALYs<-matrix(0,K,1) # a test measure  
CCosts<-matrix(0,K,1) # a test measure  
FSR<-matrix(0,K,9) # a test measure  
CSR<-matrix(0,100,3) # a test measure  
PREC<-array(0,dim=c(100,9,K)) # a test measure  
WQUALY<-matrix(0,100,K) # a test measure  
WCOST<-matrix(0,100,K) # a test measure  
 for(k in c(1:K)){ #starting simulation of K patients 
     
    S<-matrix(c(0),100,9,byrow=TRUE,dimnames = list(c(1:100),c("Adenoma-
D","Adenoma-M","Adenoma-L","CRC-L","CRC-R","CRC-D","Alive?","Death 
Cause","# OF Years With CRC"))) # patient life matrix 
    i<-1 #aging index 
    A<-0 #alive or dead index (0 is alive) 
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    W<-0 # a test measure  
    QALYs<-0 #patinet QALYs recorder 
    Costs<-0  #patient Cost recorder 
    STF<-0 # Sojourn time flag 
    RST<-101 # sojourn time 
    CF<-0 #cancer flag to distinguish cancer cases from non cancer cases 
    while(i<=100 & A==0){ #start aging from 1 to 100 for a person 
      AQ<-0 #Adding QALYs permission 
      CR<-S[i,5] #number of CRC-R adenomas in this state 
       
      if(CR>=1){ #in case the patient have at least one CRC-R adenoma 
        for(u in c(1:CR)){ #counting adenoma 
          r5<-runif(1,0,1) 
           
          if(r5>Rates[(ceiling(i/5)),19]){ #56 
             
            S[i,5]<-S[i,5]-1 
            S[i,6]<-S[i,6]+1 
            CSR[c(i:100),3]<-CSR[c(i:100),3]+1 
            CSR[c(i:100),2]<-CSR[c(i:100),2]-1 
          } 
          u<-u+1 #next adenoma 
        } 
      } 
      CL<-S[i,4] #number of CRC-L adenomas in this state 
            if(CL>=1){ #in case the patient have at least one CRC-L adenoma 
        for(r in c(1:CL)){ #counting adenoma 
          r4<-runif(1,0,1) 
           
          if(r4>Rates[(ceiling(i/5)),17]){ #45 
             
            S[i,4]<-S[i,4]-1 
            S[i,5]<-S[i,5]+1 
            CSR[c(i:100),2]<-CSR[c(i:100),2]+1 
            CSR[c(i:100),1]<-CSR[c(i:100),1]-1 
          } 
           
          r<-r+1 #next adenoma 
        } 
      } 
      L<-S[i,3] #number of large adenomas in this state 
       
      if(L>=1){ #in case the patient have at least one large adenoma 
        for(o in c(1:L)){ #counting adenoma 
          r3<-runif(1,0,1) 
          if(r3<=Rates[(ceiling(i/5)),14]){ #stage 3 to 2 
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            S[i,3]<-S[i,3]-1 
            S[i,2]<-S[i,2]+1 
          } 
                    if(r3>=(1-Rates[(ceiling(i/5)),16])){ #stage 3 to 4 
             
            if(S[i,4]==0){ #a test measure  
              CC[i]<-CC[i]+1 
              CSR[c(i:100),1]<-CSR[c(i:100),1]+1 
              SCRES[h,5]<-SCRES[h,5]+1 #a test measure  
              CF<-1 #a test measure  
                            RST<-rexp(1,(1/SojT[i])) #generate mean sojourn time 
              if(STF==0){  
                S[i,9]<-1 
                STF<-1 
              } 
            } 
             
            S[i,3]<-S[i,3]-1 
            S[i,4]<-S[i,4]+1  
          } 
          o<-o+1 #next adenoma 
        } 
      } 
       
       
      M<-S[i,2] #number of medium adenomas in this state 
       
      if(M>=1){ #in case the patient have at least one medium adenoma 
        for(m in c(1:M)){ #counting adenoma 
          r2<-runif(1,0,1) 
          if(r2<=Rates[(ceiling(i/5)),9]){ #stage 2 to 1 
            S[i,2]<-S[i,2]-1 
            S[i,1]<-S[i,1]+1 
          } 
                   if(r2>=(1-Rates[(ceiling(i/5)),11])){ #stage 2 to 3 
            S[i,2]<-S[i,2]-1 
            S[i,3]<-S[i,3]+1 
          } 
          m<-m+1 #next adenoma 
        } 
      } 
      D<-S[i,1] #number of dimunitive adenomas 
       
      if(D>=1){ #in case the patient have at least one dimunitive adenoma 
        for(l in c(1:D)){ #counting adenoma 
           
57 
          r1<-runif(1,0,1)  
          if(r1<=Rates[(ceiling(i/5)),4]){ #stage 1 to 0 
            S[i,1]<-S[i,1]-1 
          } 
         
          if(r1>=(1-Rates[(ceiling(i/5)),6])){ #stage 1 to 2 
            S[i,1]<-S[i,1]-1 
            S[i,2]<-S[i,2]+1 
          } 
          
          l<-l+1 #next adenoma 
        } 
      } 
       
       
       
      if(sum(S[i,])<n){ #checking the maximum allowed number of adenoma condition to 
see if we can have adenoma incidence or not  
        r0<-runif(1,0,1) 
        f<-0 
        for(j in c((n-sum(S[i,])):1)){#number of adenoma that can be generated 
          if(r0<=(Rates[(ceiling(i/5)),2])^(j) & f==0){ #number of adenoma that the body 
generates 
            S[i,1]<-S[i,1]+(j) #adding generated adenomas life matrix 
            f<-1 
          } 
          j<-j-1 
        } 
      }  
      if(i<=99){ #copying patient life matrix next year 
         
            S[i+1,]<-S[i,] 
             
            if(STF>0){ 
              S[i+1,9]<-S[i,9]+1 ########add one to Sojourn time counter for next year 
            } 
      }  
 
    #############Applying screening tests 
      ##########Removing adenomas via clonoscopy / a person with adenoma and not 
cancer has colonoscopy 
      if(Scenario[i]==1 & sum(S[i,(4:6)])==0){ ## removing adenomas 
        SCRES[h,13]<-SCRES[h,13]+1 
        for(g in c(1:3)){ #to apply the test on Dimunitive,Medium and Large Adenoma 
          for(e in c(1:S[i,g])){ #to go one by one on each adenoma 
            r13<-runif(1,0,1) 
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            if(S[i,g]>0 & r13<=TSen[g,1]){ 
              S[i+1,g]<-S[i+1,g]-1 
   
              CF<-1 
            } 
          } 
        } 
      } 
       ##########Removing adenomas via FS / a person with adenoma and not cancer has 
FS 
      if(Scenario[i]==4 & sum(S[i,(4:6)])==0){ ## removing adenomas 
        for(g in c(1:3)){ #to apply the test on Dimunitive,Medium and Large Adenoma 
          for(e in c(1:S[i,g])){ #to go one by one on each adenoma 
            r11<-runif(1,0,1) 
            r14<-runif(1,0,1) 
            if(S[i,g]>0 & r14<=TSen[g,4] & r11<=.34){ 
              S[i+1,g]<-S[i+1,g]-1 
               
              CF<-1 
            } 
          } 
        } 
      } 
            ######### A CRC case has Screening 
      r15<-runif(1,0,1) 
      if((sum(S[i,c(4:6)]))>0 & Scenario[i]>0){  
        if(r15<(FSF[Scenario[i]])){ 
        TT<-Scenario[i] #to clarify test type 
        if(TT==1){ 
          SCRES[h,13]<-SCRES[h,13]+1 # a measure test 
        } 
        r8<-runif(1,0,1) 
        if(r8<TSen[4,TT]){#True positive ,, terminating patient because we discover his 
CRC 
                    if(TT==2 | TT==3){ #deduct colonoscopy disutility and add colonoscopy 
cost 
            QALYs<-QALYs-Disutilities[1] #extra colonoscopy 
            Costs<-Costs+Price[1] 
            SCRES[h,14]<-SCRES[h,14]+1# a test measure  
          } 
                    S[c(i:100),7]<-i #setting the matrix life for the rest of the years to show age 
at death and cause of dead 
          S[c(i:100),8]<-TT 
          SCRES[h,(TT+5)]<-SCRES[h,(TT+5)]+1 # a test measure  
          A<-1 
          # adding QALYS based on final stage of patient 
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          if(S[i,6]>0){ #distant  
            QALYs<-QALYs+DQ[(i),3] 
           
             
            Costs<-Costs+TRC[1,3]+TRC[2,3] #adding treatment costs 
 
            AQ<-1 
          } 
                    if(S[i,5]>0 & AQ==0){ #regional  
            QALYs<-QALYs+DQ[(i),2] 
            Costs<-Costs+TRC[1,2]+TRC[2,2] 
            AQ<-1 
          } 
              if(S[i,4]>0 & AQ==0){ #localized  
            QALYs<-QALYs+DQ[(i),1]  
            Costs<-Costs+TRC[1,1]+TRC[2,1] 
 
            AQ<-1 
          } 
        } 
        #if we get False Negetive, patient will go back to system and his CRC may be 
diagnosed later 
      }} 
       ########### A healthy patient has Screening 
       if(sum(S[i,c(4:6)]==0 & Scenario[i]>0)){  
        TT<-Scenario[i] 
        r10<-runif(1,0,1) 
        if(r10 > TSpec[TT]){ # false positive  
            
          # colonoscopy  and biopsy discover the truth ,, True Negetive 
            QALYs<-QALYs-.0027 #deducting disutility for the false positive  
            if(TT==2 | TT==3){ # if patient gest the false negative from FIT or FOBT 
            Costs<-Costs+Price[1] #extra colonoscopy 
            QALYs<-QALYs-Disutilities[1] #extra colonoscopy 
            SCRES[h,14]<-SCRES[h,14]+1 # a test measure  
             
             
              if(sum(S[i,(1:3)])>0){ ## removing adenomas in case the patient has adenoma , 
(lucky patient) 
                for(g in c(1:3)){ #to apply the test on Dimunitive,Medium and Large Adenoma 
                  for(e in c(1:S[i,g])){ #to go one by one on each adenoma 
                    r13<-runif(1,0,1) 
                    if(S[i,g]>0 & r13<=TSen[g,1]){ 
                      S[i+1,g]<-S[i+1,g]-1 
                     
                      CF<-1 
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                    } 
                  } 
                } 
              } 
            } 
        } 
       
        if(TT==1){ #test is colonoscopy 
          SCRES[h,13]<-SCRES[h,13]+1 # a test measure  
        } 
      } 
      ############################# Sojourn time and self detection 
      if(A==0 & S[i,9]>=RST){ #if cancer becoms symptomatic 
        ### we add remaining QALYs and costs based on distant stage and terminate  him 
        S[c(i:100),7]<-i 
        S[c(i:100),8]<-9 
        SCRES[h,10]<-SCRES[h,10]+1 # a test measure  
        A<-1 
        DC[i]<-DC[i]+1 
         
        # adding QALYS based on distant stage 
          QALYs<-QALYs+DQ[i,3] 
 
          Costs<-Costs+TRC[1,3]+TRC[2,3] 
 
          AQ<-1 
      } 
       
       
      ########### terminating  a CRC case before sojourn time  
       
      if(A==0 & S[i,6]>0){ #killing a distant case  
         
        r7<-runif(1,0,1) 
        if(r7<= ASDR[i,3]){  
           
          S[c(i:100),7]<-i #updating teh life matrix 
          S[c(i:100),8]<-6 
          SCRES[h,11]<-SCRES[h,11]+1 #a test measure  
          A<-1 
          DC[i]<-DC[i]+1 
          FSR[k,]<-S[i,] 
          CSR[c(i:100),3]<-CSR[c(i:100),3]-1 # a test measure  
        } 
      }  
            if(A==0 & S[i,5]>0){ #terminating a regional case  
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                r7<-runif(1,0,1) 
        if(r7<= ASDR[i,2]){ 
           
          S[c(i:100),7]<-i #updating the life matirx 
          S[c(i:100),8]<-6 
          SCRES[h,11]<-SCRES[h,11]+1 
          A<-1 
          DC[i]<-DC[i]+1 
          FSR[k,]<-S[i,] 
          CSR[c(i:100),2]<-CSR[c(i:100),2]-1 #a test measure  
        } 
      }  
       
      if(A==0 & S[i,4]>0){ #killing a localized case   
            r7<-runif(1,0,1) 
        if(r7<= ASDR[i,1]){ 
           
          S[c(i:100),7]<-i #updating the life matrix 
          S[c(i:100),8]<-6 
          SCRES[h,11]<-SCRES[h,11]+1 #a test measure  
          A<-1 
          DC[i]<-DC[i]+1 
          FSR[k,]<-S[i,] 
          CSR[c(i:100),1]<-CSR[c(i:100),1]-1 
        } 
      }  
    
      ###########killing a non crc cases because of natural causes  
      r9<-runif(1,0,1) 
      if(r9<=DR[i] & A==0 & sum(S[i,(4:6)])==0){  
        S[c(i:100),7]<-i # updating the life matrix  
        S[c(i:100),8]<-10 
        SCRES[h,12]<-SCRES[h,12]+1 # a test measure  
        A<-1 
        DC[i]<-DC[i]+1 
      } 
      #######adding QALYs 
            if(AQ==0){#adding cost and  QALYs for the patient  
        QALYs<-QALYs+Utilities[i,1] 
        AQ<-1 
      } 
         
      if(Scenario[i]>0){ 
          QALYs<-QALYs - Disutilities[Scenario[i]] 
          Costs<-Costs+Price[Scenario[i]] 
      } 
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      #end of adding cost and QALYs for the patient 
      i<-i+1 #next year of the person's life 
    } # end of simulating a person 
        BQALYs[k]<-QALYs # recording this patient QALYs 
      BCosts[k]<-Costs # recording this patient cost 
        if(CF==1){ # a test measure  
      CQALYs[k]<-QALYs 
      CCosts[k]<-Costs 
    }   
    for (ab in c(1:100)){#a test measure  
      if (sum(S[ab,c(4:6)])>0){ 
        AC[ab]<-AC[ab]+1 
      } 
    } 
    PREC[,,k]<-S # a test measure  
    k<-k+1 #next person 
  } #end of simulating K people 
AP<-K-cumsum(DC) #Alive Population 
########################################### Population Matrix 
PO<-matrix(0,18,1)  
for(i in c(1:16)){ 
  PO[i+1]<-sum(AP[(5*i):(5*i+4)]) 
} 
PO[1]<-sum(AP[1:4]) 
PO[18]<-sum(AP[85:100]) 
###########################################Cancer Cases Matrix 
CCases<-matrix(0,18,1)  
for(i in c(1:16)){ 
  CCases[i+1]<-sum(CC[(5*i):(5*i+4)]) 
} 
CCases[1]<-sum(CC[1:4]) 
CCases[18]<-sum(CC[85:100]) 
###########################################Final result 
MRates<-matrix(0,18,1)  
for(i in c(1:18)){ 
  MRates[i]<-((100000*CCases[i])/(PO[i])) 
} 
Temp<-t(MRates) 
BIGRES[x,]<-Temp[1,] 
########################################### absolute Error and Square Error 
between Seer and my rates 
Difference<-matrix(0,18,1)  
DifferenceS<-matrix(0,18,1) 
for(i in c(1:18)){ 
  Difference[i]<-((SEER_Males[i])-(MRates[i])) 
  DifferenceS[i]<-((SEER_Males[i])-(MRates[i]))^2 
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} 
ERROR<-sum(abs(Difference)) 
MSERROR<-sum(DifferenceS) 
BERROR[x]<-ERROR 
BMSERROR[x]<-MSERROR 
BDIF[x,]<-t(Difference[,1]) 
########################################### gathering all row result in a matrix 
and write it 
Result<-cbind(AP,CC,AC) 
colnames(Result)<-c("Population","New Cancer cases","Alive cancer cases") 
###########################################Putting final results and SEER 
together  
COMP<-cbind(MRates,SEER_Males) 
#COMP 
########################################### 
}#calibration ends 
SCRES[h,1]<-mean(BQALYs) # patinets expected QALYs 
SCRES[h,2]<-sd(BQALYs) #  QALYs standard deviation 
SCRES[h,3]<-mean(BCosts) # patinets expected costs 
SCRES[h,4]<-sd(BCosts) # cost standard deviation 
 
SCRES[h,15]<-mean(CQALYs[CQALYs!=0]) # test measures  
SCRES[h,16]<-sd(CQALYs[CQALYs!=0]) # test measures 
SCRES[h,17]<-mean(CCosts[CCosts!=0]) # test measures 
SCRES[h,18]<-sd(CCosts[CCosts!=0]) # test measures 
 
SCRES[h,19]<-K-length(which(BQALYs==0)) # test measures 
SCRES[h,20]<-K-length(which(BCosts==0)) # test measures 
SCRES[h,21]<-K-length(which(CQALYs==0)) # test measures 
SCRES[h,22]<-K-length(which(CCosts==0)) # test measures 
 
write.csv(SCRES,file = "C:\\Users\\amirhosein.fouladi\\Dropbox\\LA 
Tech\\Research\\Dessertation\\ACL\\Scenarios\\SCRES10-1-27-41-81.csv") 
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